At Roche you can show up as yourself, embraced for the unique qualities you bring. Our culture encourages personal expression, open dialogue, and genuine connections, where you are valued, accepted and respected for who you are,
We are the people who give possibilities purpose BD is one of the largest global medical technology companies in the world. Advancing the world of health is our Purpose, and it’s no small feat. It takes the
Minimum qualifications: Bachelors degree or equivalent practical experience. 7 years of experience in business development, partnerships, management consulting, in the payments, e-commerce/retail, technology industries on EMEA market. Experience in signing and negotiating agreements, business development, partner
The Client Director plays a pivotal role in driving the companys growth strategy, commercial effectiveness, and client engagement across Switzerland. This role is responsible for leading business development activities while maintaining a strong external client focus,
# Head BD&L Transactions ImmunologyREQ- Jul 01, 2026SwitzerlandAvailable in:English# Summary#LI-Hybrid Location: Basel, Switzerland What if the deals you shape today could define the future of healthcare? As Head BD&L Transactions, Immunology, you’ll be at the heart of Novartis’
The Director, BD Early Stage leads the assessment of early-stage external innovation opportunities from Due Diligence Stage 2 to negotiation of a Non-Binding Offer (NBO). The role integrates evolving scientific advances, therapeutic trends and market dynamics to
Alentis Therapeutics, the Claudin-1 Company, is on a mission to treat cancer and reverse fibrosis. To this end, we are rapidly advancing a clinical pipeline of anti-Claudin-1 monoclonal antibodies. Our team is committed to unlocking the
Contractor SVP Clinical Development Fibrosis (Hepatology) Alentis Therapeutics AG - Allschwil The SVP of Clinical Development Fibrosis (Hepatology), reporting to the Chief Medical Officer, will oversee clinical research, medical management, and study execution for the Company’s